From the perspective of a lipid and atherosclerosis specialist, assuming that the barriers to PCSK9 inhibitors are reduced, which patients at risk for—or with confirmed—ASCVD represent the best, risk-directed candidates for LDL-C lowering?
From the perspective of a lipid and atherosclerosis specialist, assuming that the barriers to PCSK9 inhibitors are reduced, which patients at risk for—or with confirmed—ASCVD represent the best, risk-directed candidates for LDL-C lowering?
Created by
Presenter
Full Professor of Pharmacology University of Milano Director, Laboratory for the Study of Lipoproteins and Atherosclerosis Director, Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis